GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
E

Enveric Biosciences ENVB · USD

Health Care · US listing · 🇺🇸 United States

Compare

1.44

+1.41%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Enveric Biosciences

From its filings with the US Securities and Exchange Commission

SEC filings

Enveric Biosciences is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ENVB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2019, it reported revenue of $39.9m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
21 Jul 2009
Employees
25
Website
enveric.com ↗
Head office
245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE, MA, 02142
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Michael WebbIndependent Chairman of the Board$195,048
  • Dr. Joseph TuckerChief Executive Officer, Director, since 2021$611,533
  • Mr. Kevin CoveneyChief Financial Officer$478,002
  • Dr. Peter FacchiniChief Innovation Officer$274,580
  • Dr. Sheila DeWittIndependent Director$39,695
  • Mr. George KeglerIndependent Director$79,048
  • Mr. Frank PasqualoneIndependent Director$85,548
  • Dr. Marcus SchabackerIndependent Director$76,048
  • Mr. David IrishInvestor Relations Officer, since 2025

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Naples Florida with a focus on cannabinoid medicines and combination therapies.
  • Develops novel small-molecule therapeutics for anxiety, depression, and addiction disorders.
  • Owns a robust intellectual property portfolio including New Chemical Entities for mental health indications.

Weaknesses

  • Limited employee count of 25 full-time employees.
  • IPO occurred in 2009, indicating a long-standing but potentially outdated business model.
  • Lead program EB-373 is in preclinical development, suggesting early-stage drug development.

Opportunities

  • Advancing EVM301 Series therapeutics that eliminate psychedelic experiences and reduce safety concerns.
  • Expanding the IP portfolio through Psybrary for specific mental health indications.
  • Potential market growth in novel treatments for anxiety, depression, and addiction disorders.

Threats

  • Preclinical stage of lead program EB-373 may face development and regulatory challenges.
  • Competition in the pharmaceutical sector for mental health treatments.
  • Dependence on a single lead program for significant development progress.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.